Date: 2017-01-16
Type of information: Development agreement
Compound: MicroJet Reactor (MJR®) based dermatological product
Company: Leon-nanodrugs (Germany) Bionpharma (USA - NJ)
Therapeutic area: Dermatological diseases
Type agreement: development
Action mechanism: In the MicroJetReactor (MJR®), two fine impinging jets of fluid containing dissolved compounds collide with each other in the center of an inert gas-purged chamber. The small diameter and the high velocity of the jets together with high shear forces result in a very rapid and intense mixing and precipitation of insoluble compounds. Using this technology, encapsulation of specific substances in the interior of the forming nanoparticle is feasible. At the end of this “one step reaction” stands the final nanoparticle ready for further processing. Thus, in a downstream or serially connected MicroJetReactor the resulting particles can be surface modified/coated.
Disease:
Details: * On January 16, 2017, leon-nanodrugs and Bionpharma announced the global cooperation for the development of a dermatological product using leon-nanodrugs’ proprietary nanotechnology platform –MicroJet Reactor (MJR®). leon and Bionpharma will co-share the development of this product. Development will be done at Leon’s US-based formulation partner CoreRx from Clearwater, Florida, a comprehensive Contract Development and Manufacturing Organization. CoreRx’s facility houses leon-nanodrugs’ proprietary nanotechnology platform – MicroJet Reactor (MJR), thereby enabling leon to gain fast access to the key US market. Marketing and distribution of the product will be through Bionpharma in the US and other markets. It is estimated that over 60% of pharmaceutical API’s are poorly soluble in water. leon’s MJR technology offers reformulation options that not only address this issue, but can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability, improving onset of action, etc.
Financial terms:
Latest news:
